Welcome to Spring Bank Pharmaceuticals, Inc.

Spring Bank Pharmaceuticals is an IND-stage drug discovery company. Based on our proprietary platform technology, we are developing a pipeline of products representing a new class of pharmaceuticals we call small molecule nucleic acid hybrids “SMNH” with a wide range of applications and multi-billion dollar market potential.

These rationally designed molecules combine the target selectivity and specificity advantages of nucleic-acid-based therapeutics, like RNAi and antisense oligonucleotides, with the drug-like properties of classical pharmaceuticals, including oral delivery, good pharmacokinetics, low side effects and ease of manufacture.  Our most advanced product is SB 9200, a potential breakthrough drug for Hepatitis B and C with both direct antiviral and immune stimulatory activities, for which we plan to begin Phase I trials in 2012. Behind SB 9200 are drug discovery programs for COPD, other viral infections and cancer.

About Hepatitis

Over 350 million people are chronically infected with HBV virus worldwide. The HBV virus is a DNA virus which incorporates into the hepatocyte DNA. Read More >>

Approximately 170 million people worldwide and 4 million in the United States are infected with HCV. HCV infection is one of the most significant public health threats facing Americans.
Read More >>